Strong data from the ROADS clinical trial highlight the potential of GammaTile® cesium-131 collagen tile-based radiation therapy (TBRT) to improve outcomes for patients with brain metastases requiring surgery. In the multicenter Phase 3 study, immediate placement of tile-based radiation during surgery resulted in significantly lower rates of tumor regrowth, a greater likelihood of living longer without recurrence, and significantly improved overall survival compared to standard of care, without increased side effects. These findings, published as a Rapid Communication in the Journal of Clinical Oncology, reinforce the value of delivering targeted radiation therapy at the time of surgery. Based on the results, the study authors conclude that GammaTile should be considered a standard-of-care option for patients with newly diagnosed operable brain metastases. Read the press release: na2.hubs.ly/H083mDx0 #ROADSTrial #GammaTile #JCO @JCO_ASCO See full prescribing information at na2.hubs.ly/H083mDy0

Join GammaTile for a clinical lunch symposium, “ROADS Phase 3 Evidence: Published Results and What They Mean for Newly Diagnosed Brain Metastases,” during SYM10A/B: Brain Tumor Update - Malignant and Benign at the Congress of Neurological Surgeons (@CNS_Update) Annual Meeting. Add to calendar: na2.hubs.ly/H08CTv00 #2026CNS See full prescribing information at na2.hubs.ly/H08CTv10

The Phase 3 ROADS Trial findings were recently reported by Nuclio Media, a leading publication dedicated to the business of nuclear medicine. Read the article: na2.hubs.ly/H08BhJh0 See full prescribing information at na2.hubs.ly/H08BhK90

Close out Day 3 of #2026CNS at our Clinical Dinner Symposium, where you’ll learn more about the latest GammaTile data. Reserve Your Spot: na2.hubs.ly/H08yTW10 See full prescribing information at na2.hubs.ly/H08yTW30

We recently welcomed Columbia University Irving Medical Center/NewYork-Presbyterian Hospital as the latest GammaTile Center of Excellence. Neurosurgeon Brian J.A. Gill, MD, shares what this recognition means for the team and their dedication to advancing brain tumor care. Read the press release: na2.hubs.ly/H08xxp30 #GammaTileCOE See full prescribing information at na2.hubs.ly/H08xxp40

Join GammaTile for a clinical lunch symposium, “ROADS Phase 3 Evidence: Published Results and What They Mean for Newly Diagnosed Brain Metastases,” during SYM10A/B: Brain Tumor Updates - Malignant and Benign at the Congress of Neurological Surgeons (@CNS_Update) Annual Meeting. Add to calendar: na2.hubs.ly/H08wsSN0 See full prescribing information at na2.hubs.ly/H08wsTh0

Hear from radiation oncologist and GammaTile practitioner Dr. Lindsey Sloan on M Health Fairview University of Minnesota Medical Center’s designation as a GammaTile Center of Excellence this past March. Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School. #GammaTileCOE See full prescribing information at na2.hubs.ly/H08tc7K0

Are you attending #2026CNS? Join us at one of our educational events to hear how GammaTile is improving tumor control in operable brain tumors. Explore the GammaTile schedule: na2.hubs.ly/H08rtz50 See full prescribing information at na2.hubs.ly/H08rtxV0

GammaTile achieved 98.7% local tumor control by 12 months, compared to 84.6% for standard of care, reducing the risk of local tumor recurrence at 12 months by more than 90% (HR: 0.07, 95% CI: 0.01–0.56; p=0.012)1* In the manuscript's conclusion, the study authors state that GammaTile should be considered a standard-of-care option for patients with newly diagnosed brain metastases. Read the publication: na2.hubs.ly/H08q1gf0 Reference: Weinberg JS, Imber BS, DiNapoli V, et al. J Clin Oncol. 2026. *Local control calculated as 100% minus the cumulative incidence of surgical bed recurrence (SBR) expressed as a percentage. See full prescribing information at na2.hubs.ly/H08q1gg0

At #ASTRO26, we invited attendees for an evening on the waterfront to learn more about the ROADS RCT data and best practices for tile-based radiation therapy integration.   The GammaTile team welcomed Lindsey Sloan, MD, PhD, and M. Sean Peach, MD, PhD, to present how Tile-Based Radiation Therapy (TBRT) with GammaTile is revolutionizing treatment timing and local control by closing the treatment gap.   Thank you to everyone who joined us for an evening of great conversation, and to Drs. Sloan and Peach for sharing their insights. We’re eager to keep the momentum going as we work together to close the treatment gap for patients with operable brain tumors.

We are proud to announce Columbia University Irving Medical Center/New York-Presbyterian Hospital as our latest GammaTile Center of Excellence, acknowledging their outstanding clinical expertise in the GammaTile procedure. The following physicians have received this designation: - Brian J.A. Gill, MD, Neurological Surgeon - Michael B. Sisti, MD, Neurological Surgeon - Tony Wang, MD, Radiation Oncologist Read the press release: na2.hubs.ly/H08m2wv0 See full prescribing information at na2.hubs.ly/H08m2ww0

St. Luke's Boise Medical Center has been named our newest GammaTile Center of Excellence, recognizing their expertise in the GammaTile procedure and commitment to advancing brain tumor treatment. The following physicians have received this designation: - Edward A. Duckworth, MD - David P. Bray, MD - Derek L. Martinez, MD - Benjamin G. McGahan, MD - Cameron S. Thorpe, MD - Tonya L. Kuhn, MD - Stephen C. Smith, MD - Timothy E. Sawyer, MD - Amy Geyer, MS Read the press release: na2.hubs.ly/H08dxTr0 #GammaTile #GammaTileCOE See full prescribing information at na2.hubs.ly/H08dxSR0

Are you attending #ASTRO26? Our GammaTile Clinical Dinner Symposium, “Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy,” takes place tomorrow, September 27th Reserve your spot: na2.hubs.ly/H081r_m0 Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School. M. Sean Peach, MD, PhD, is an Associate Professor at The Brody School of Medicine at East Carolina University and Director of Brachytherapy Services at ECU Health. See full prescribing information at na2.hubs.ly/H081r-X0

#ASTRO26 is two days away. Join the GammaTile team at 12 PM this Sunday, September 27th, for an Industry Expert Theater, “Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases.” Add to calendar: na2.hubs.ly/H081hMS0 Brandon Imber, MD, MA, is an Assistant Attending Radiation Oncologist at Memorial Sloan Kettering Cancer Center. Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School. See full prescribing information at na2.hubs.ly/H081hMT0

Are you heading to Boston, MA, for #ASTRO26 this weekend? Our GammaTile Clinical Dinner Symposium, “Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy,” takes place this Sunday, September 27th. Reserve your spot: na2.hubs.ly/H07-l9Y0 See full prescribing information at na2.hubs.ly/H07-l9Z0

#ASTRO26 kicks off this weekend. Join the GammaTile team at 12 PM this Sunday, September 27th, for an Industry Expert Theater, “Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases.” Add to calendar: na2.hubs.ly/H07Zkng0 Note: The Industry Expert Theater content and views expressed therein are those of the Exhibitor and not of ASTRO. See full prescribing information at na2.hubs.ly/H07Zknh0

#ASTRO26 is right around the corner. Mark your calendars for 12 PM on Sunday, September 27th, to join us for an Industry Expert Theater, titled “Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases.” Add to calendar: na2.hubs.ly/H07Q99_0 See full prescribing information at na2.hubs.ly/H07Q9b10

Join us for a beverage break during “SYM10A: Brain Tumor Update - Management of Malignant Brain Tumors,” to learn more about GammaTile at the Congress of Neurological Surgeons (@CNS_Update) 2026 Annual Meeting this November! Add to calendar: na2.hubs.ly/H07L8yP0 See full prescribing information at na2.hubs.ly/H07L8yQ0